Hypertrophic scarring and keloids: Pathomechanisms and current and emerging treatment strategies

Molecular Medicine

Volumn 17, Issue 1-2, 2011, Pages 113-125

  Gauglitz, Gerd G ^a,b   Korting, Hans C ^a   Pavicic, Tatiana ^a   Ruzicka, Thomas ^a   Jeschke, Marc G ^b,c,d,e  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b University of Texas Medical Branch School of Medicine   (United States)

^c Ross Tilley Burn Centre and   (Canada)

^d Sunnybrook Health Sciences Centre   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BLEOMYCIN SULFATE; CONTRACTUBEX; CORTICOSTEROID; DECORIN; FLAVONOID; FLUOROURACIL; IMIQUIMOD; JUVIDEX; KAEMPFEROL; MANNOSE 6 PHOSPHATE; MATRIX METALLOPROTEINASE; MEDERMA; PLACEBO; QUERCETIN; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA3; SILICONE GEL; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; APOPTOSIS; ARTICLE; BASAL CELL CARCINOMA; BRACHYTHERAPY; BURNING SENSATION; CLINICAL FEATURE; CONDYLOMA ACUMINATUM; CONTRACTURE; CRYOTHERAPY; DERMIS; DRUG MECHANISM; ELECTRON THERAPY; FIBROBLAST; FIBROGENESIS; FLU LIKE SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERPIGMENTATION; HYPERTROPHIC SCAR; INFLAMMATION; INJECTION SITE PAIN; KELOID; KERATINOCYTE; LOW LEVEL LASER THERAPY; PAIN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; SCAR FORMATION; SIGNAL TRANSDUCTION; SKIN ATROPHY; TELANGIECTASIA; ULCER; WOUND CONTRACTION; WOUND HEALING;

CICATRIX, HYPERTROPHIC; HUMANS; KELOID; WOUND HEALING;

EID: 78651471059     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2009.00153     Document Type: Article

References (141)

1. Sund B. (2000) New Developments in Wound Care. PJB Publications, London, pp. 1-255.
2. Berman B, Bieley HC. (1995) Keloids. J. Am. Acad. Dermatol. 33:117-123.
3. Peacock EE Jr, Madden JW, Trier WC. (1970) Biologic basis for the treatment of keloids and hypertrophic scars. South. Med. J. 63:755-760.
4. Mancini RE, Quaife JV. (1962) Histogenesis of experimentally produced keloids. J. Invest. Dermatol. 38:143-181.
5. Atiyeh BS. (2007) Nonsurgical management of hypertrophic scars: evidence-based therapies, standard practices, and emerging methods. Aesthetic. Plast. Surg. 31:468-494.
6. Slemp AE, Kirschner RE. (2006) Keloids and scars: a review of keloids and scars, their pathogenesis, risk factors, and management. Curr. Opin. Pediatr. 18:396-402.
7. Wheeland RG. (1996) Keloids and hypertrphic scars. In: Cutaneous Medicine and Surgery. Arndt KA, Robinson JK, Leboit PE, Wintroub BU (eds.). Saunders Elsevier, Philadelphia, pp. 900-905.
8. Alster TS, West TB. (1997) Treatment of scars: a review. Ann. Plast. Surg. 39:418-432.
9. Hawkins HK. (2007) Pathophysiology of the burn scar. In: Total Burn Care. Herndon DN (ed.) Saunders Elsevier, Philadelphia, pp. 608-619.
10. Murray JC. (1994) Keloids and hypertrophic scars. Clin. Dermatol. 12:27-37.
11. Al-Attar A, et al. (2006) Keloid pathogenesis and treatment. Plast. Reconstr. Surg. 117:286-300.
12. From L, Assad D. (1993) Neoplasms, pseudoneoplasms, and hyperplasia of supporting tissue origin. In: Dermatology in General Medicine. Jeffers JD, Englis MR (eds.). McGraw-Hill, New York, pp. 1198-99.
13. Muir IF. (1990) On the nature of keloid and hypertrophic scars. Br. J. Plast. Surg. 43:61-9.
14. Niessen FB, Spauwen PH, Schalkwijk J, Kon M. (1999) On the nature of hypertrophic scars and keloids: a review. Plast. Reconstr. Surg. 104:1435-58.
15. Leventhal D, Furr M, Reiter D. (2006) Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature. Arch. Facial. Plast. Surg. 8:362-8.
16. Sephel GC, Woodward SC. (2001) Repair, regeneration, and fibrosis. In: Rubin's Pathology. Rubin E (ed.). Lippincott, Williams & Wilkins, Baltimore, pp. 84-117.
17. Oluwasanmi JO. (1974) Keloids in the African. Clin. Plast. Surg. 1:179-95.
18. Moustafa MF, Abdel-Fattah MA, Abdel-Fattah DC. (1975) Presumptive evidence of the effect of pregnancy estrogens on keloid growth: case report. Plast. Reconstr. Surg. 56:450-3.
19. Deitch EA, et al. (1983) Hypertrophic burn scars: analysis of variables. J. Trauma. 23:895-8.
20. Lewis WH, Sun KK. (1990) Hypertrophic scar: a genetic hypothesis. Burns. 16:176-8.
21. Murray CJ, Pinnel SR. (1992) Keloids and excessive dermal scarring. In: Woundhealing, Biochemical and Clinical Aspects. Cohen IK, Diegelmann RF, Lindblad WJ (eds.). Saunders Elsevier, Philadelphia, pp. 500-9.
22. Bayat A, et al. (2005) Keloid disease: clinical relevance of single versus multiple site scars. Br. J. Plast. Surg. 58:28-37.
23. Marneros AG, et al. (2004) Genome scans provide evidence for keloid susceptibility loci on chromosomes 2q23 and 7p11. J. Invest. Dermatol. 122:1126-32.
24. Brown JJ, Ollier WE, Thomson W, Bayat A. (2008) Positive association of HLA-DRB1*15 with keloid disease in Caucasians. Int. J. Immunogenet. 35:303-307.
25. Ford LC, King DF, Lagasse LD, Newcomer V. (1983) Increased androgen binding in keloids: a preliminary communication. J. Dermatol. Surg. Oncol. 9:545-7.
26. Schierle HP, Scholz D, Lemperle G. (1997) Elevated levels of testosterone receptors in keloid tissue: an experimental investigation. Plast. Reconstr. Surg. 100:390-6.
27. Placik OJ, Lewis VL Jr. (1992) Immunologic associations of keloids. Surg. Gynecol. Obstet. 175:185-93.
28. Smith CJ, Smith JC, Finn MC. (1987) The possible role of mast cells (allergy) in the production of keloid and hypertrophic scarring. J. Burn Care Rehabil. 8:126-31.
29. Ramakrishnan KM, Thomas KP, Sundararajan CR. (1974) Study of 1,000 patients with keloids in South India. Plast. Reconstr. Surg. 53:276-80.
30. Tredget EE, Nedelec B, Scott PG, Ghahary A. (1997) Hypertrophic scars, keloids, and contractures: the cellular and molecular basis for therapy. Surg. Clin. North Am. 77:701-30.
31. Brown JJ, Bayat A. (2009) Genetic susceptibility to raised dermal scarring. Br. J. Dermatol. 161:8-18.
32. Armour A, Scott PG, Tredget EE. (2007) Cellular and molecular pathology of HTS: basis for treatment. Wound Repair Regen. 15 Suppl 1:S6-S17.
33. Wynn TA. (2004) Fibrotic disease and the T(H)1/ T(H)2 paradigm. Nat. Rev. Immunol. 4:583-94.
34. Doucet C, et al. (1998) Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J. Clin. Invest. 101:2129-39.
35. Kamp DW. (2003) Idiopathic pulmonary fibrosis: the inflammation hypothesis revisited. Chest. 124:1187-90.
36. Ladak A, Tredget EE. (2009) Pathophysiology and management of the burn scar. Clin. Plast. Surg. 36:661-74.
37. Butler PD, Longaker MT, Yang GP. (2008) Current progress in keloid research and treatment. J. Am. Coll. Surg. 206:731-41.
38. Ishihara H, et al. (2000) Keloid fibroblasts resist ceramide-induced apoptosis by overexpression of insulin-like growth factor I receptor. J. Invest. Dermatol. 115:1065-71.
39. Tuan TL, Nichter LS. (1998) The molecular basis of keloid and hypertrophic scar formation. Mol. Med. Today. 4:19-24.
40. Smith JC, et al. (2008) Gene profiling of keloid fibroblasts shows altered expression in multiple fibrosis- associated pathways. J. Invest. Dermatol. 128:1298-310.
41. Bullard KM, Longaker MT, Lorenz HP. (2003) Fetal wound healing: current biology. World J. Surg. 27:54-61.
42. Szulgit G, et al. (2002) Alterations in fibroblast alpha1beta1 integrin collagen receptor expression in keloids and hypertrophic scars. J. Invest. Dermatol. 118:409-15.
43. Kose O, Waseem A. (2008) Keloids and hypertrophic scars: are they two different sides of the same coin? Dermatol. Surg. 34:336-46.
44. Bock O, et al. (2005) Studies of transforming growth factors beta 1-3 and their receptors I and II in fibroblast of keloids and hypertrophic scars. Acta. Derm. Venereol. 85:216-20.
45. Schmid P, et al. (1998) Enhanced expression of transforming growth factor-beta type I and type II receptors in wound granulation tissue and hypertrophic scar. Am. J. Pathol. 152:485-93.
46. Lee TY, et al. (1999) Expression of transforming growth factor beta 1, 2, and 3 proteins in keloids. Ann. Plast. Surg. 43:179-84.
47. Xia W, et al. (2004) Complex epithelial-mesenchymal interactions modulate transforming growth factorbeta expression in keloid-derived cells. Wound Repair Regen. 12:546-56.
48. Lu L, et al. (2005) The temporal effects of anti- TGF-beta1, 2, and 3 monoclonal antibody on wound healing and hypertrophic scar formation. J. Am. Coll. Surg. 201:391-7.
49. Cordeiro MF, et al. (2003) Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome. Gene Ther. 10:59-71.
50. Shah M, Foreman DM, Ferguson MW. (1992) Control of scarring in adult wounds by neutralizing antibody to transforming growth factor beta. Lancet. 339:213-4.
51. Shah M, Foreman DM, Ferguson MW. (1995) Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J. Cell. Sci. 108(Pt 3): 985-1002.
52. Cutroneo KR. (2007) TGF-beta-induced fibrosis and SMAD signaling: oligo decoys as natural therapeutics for inhibition of tissue fibrosis and scarring. Wound Repair Regen. 15 Suppl 1: S54-S60.
53. ten Dijke P, Hill CS. (2004) New insights into TGF-beta-Smad signalling. Trends Biochem. Sci. 29:265-73.
54. Kopp J, et al. (2005) Abrogation of transforming growth factor-beta signaling by SMAD7 inhibits collagen gel contraction of human dermal fibroblasts. J. Biol. Chem. 280:21570-6.
55. Wang Z, et al. (2007) Inhibition of Smad3 expression decreases collagen synthesis in keloid disease fibroblasts. J. Plast. Reconstr. Aesthet. Surg. 60:1193-9.
56. Nakao A, et al. (1997) Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature. 389:631-5.
57. Dooley S, et al. (2003) Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology. 125:178-91.
58. Chen MA, Davidson TM. (2005) Scar management: prevention and treatment strategies. Curr. Opin. Otolaryngol. Head Neck Surg. 13:242-7.
59. Terada Y, et al. (2002) Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-obstructed kidney. Kidney Int. 61: S94-8.
60. Niessen FB, Schalkwijk J, Vos H, Timens W. (2004) Hypertrophic scar formation is associated with an increased number of epidermal Langerhans cells. J. Pathol. 202:121-9.
61. Andriessen MP, Niessen FB, Van de Kerkhof PC, Schalkwijk J. (1998) Hypertrophic scarring is associated with epidermal abnormalities: an immunohistochemical study. J. Pathol. 186:192-200.
62. Lim IJ, et al. (2001) Investigation of the influence of keloid-derived keratinocytes on fibroblast growth and proliferation in vitro. Plast. Reconstr. Surg. 107:797-808.
63. Eming SA, Krieg T, Davidson JM. (2007) Inflammation in wound repair: molecular and cellular mechanisms. J. Invest. Dermatol. 127:514-25.
64. Moyer KE, Saggers GC, Ehrlich HP. (2004) Mast cells promote fibroblast populated collagen lattice contraction through gap junction intercellular communication. Wound Repair. Regen. 12:269-75.
65. Noli C, Miolo A. (2001) The mast cell in wound healing. Vet. Dermatol. 12:303-13.
66. Ghahary A, Ghaffari A. (2007) Role of keratinocytefibroblast cross-talk in development of hypertrophic scar. Wound Repair Regen. 15 Suppl 1: S46-53.
67. Ghahary A, et al. (1996) Collagenase production is lower in post-burn hypertrophic scar fibroblasts than in normal fibroblasts and is reduced by insulin-like growth factor-1. J. Invest. Dermatol. 106:476-81.
68. Birkedal-Hansen H, et al. (1993) Matrix metalloproteinases: a review. Crit. Rev. Oral. Biol. Med. 4:197-250.
69. Johnson-Wint B. (1988) Do keratinocytes regulate fibroblast collagenase activities during morphogenesis? Ann. N. Y. Acad. Sci. 548:167-73.
70. Fujiwara M, Muragaki Y, Ooshima A. (2005) Keloid-derived fibroblasts show increased secretion of factors involved in collagen turnover and depend on matrix metalloproteinase for migration. Br. J. Dermatol. 153:295-300.
71. Neely AN, et al. (1999) Gelatinase activity in keloids and hypertrophic scars. Wound Repair Regen. 7:166-71.
72. Mauviel A. (1993) Cytokine regulation of metalloproteinase gene expression. J. Cell. Biochem. 53:288-95.
73. Zhang Y, McCluskey K, Fujii K, Wahl LM. (1998) Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNFalpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanisms. J. Immunol. 161:3071-6.
74. McQuibban GA, et al. (2002) Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood. 100:1160-7.
75. McQuibban GA, et al. (2000) Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science. 289:1202-6.
76. Scott PG, et al. (1996) Chemical characterization and quantification of proteoglycans in human post-burn hypertrophic and mature scars. Clin. Sci. (Lond). 90:417-25.
77. Sayani K, et al. (2000) Delayed appearance of decorin in healing burn scars. Histopathology. 36:262-72.
78. Zhang Z, et al. (2009) Recombinant human decorin inhibits TGF-beta1-induced contraction of collagen lattice by hypertrophic scar fibroblasts. Burns. 35:527-37.
79. Mukhopadhyay A, et al. (2010) Syndecan-2 and decorin: proteoglycans with a difference- implications in keloid pathogenesis. J. Trauma. 68:999-1008.
80. Nedelec B, et al. (2001) Myofibroblasts and apoptosis in human hypertrophic scars: the effect of interferon-alpha2b. Surgery. 130:798-808.
81. Bond JS, et al. (2008) Maturation of the human scar: an observational study. Plast. Reconstr. Surg. 121:1650-8.
82. Bond JS, et al. (2008) Scar redness in humans: how long does it persist after incisional and excisional wounding? Plast. Reconstr. Surg. 121:487-96.
83. Mustoe TA, et al. (2002) International clinical recommendations on scar management. Plast. Reconstr. Surg. 110:560-71.
84. Durani P, Bayat A. (2008) Levels of evidence for the treatment of keloid disease. J. Plast. Reconstr. Aesthet. Surg. 61:4-17.
85. Mutalik S. (2005) Treatment of keloids and hypertrophic scars. Indian J. Dermatol. Venereol. Leprol. 71:3-8.
86. Baur PS, et al. (1976) Ultrastructural analysis of pressure-treated human hypertrophic scars. J. Trauma. 16:958-67.
87. Macintyre L, Baird M. (2006) Pressure garments for use in the treatment of hypertrophic scars-a review of the problems associated with their use. Burns. 32:10-5.
88. Kelly AP. (2004) Medical and surgical therapies for keloids. Dermatol. Ther. 17:212-8.
89. Reno F, et al. (2003) In vitro mechanical compression induces apoptosis and regulates cytokines release in hypertrophic scars. Wound Repair Regen. 11:331-6.
90. Van den Kerckhove E, et al. (2005) The assessment of erythema and thickness on burn related scars during pressure garment therapy as a preventive measure for hypertrophic scarring. Burns. 31:696-702.
91. Sawada Y, Sone K. (1992) Hydration and occlusion treatment for hypertrophic scars and keloids. Br. J. Plast. Surg. 45:599-603.
92. Fulton JE, Jr. (1995) Silicone gel sheeting for the prevention and management of evolving hypertrophic and keloid scars. Dermatol. Surg. 21:947-51.
93. Reish RG, Eriksson E. (2008) Scar treatments: preclinical and clinical studies. J. Am. Coll. Surg. 206:719-30.
94. Phan TT, et al. (2003) Quercetin inhibits fibronectin production by keloid-derived fibroblasts. Implication for the treatment of excessive scars. J. Dermatol. Sci. 33:192-4.
95. Jackson BA, Shelton AJ. (1999) Pilot study evaluating topical onion extract as treatment for postsurgical scars. Dermatol. Surg. 25:267-9.
96. Chung VQ, Kelley L, Marra D, Jiang SB. (2006) Onion extract gel versus petrolatum emollient on new surgical scars: prospective doubleblinded study. Dermatol. Surg. 32:193-7.
97. Beuth J, et al. (2006) Safety and efficacy of local administration of contractubex to hypertrophic scars in comparison to corticosteroid treatment. Results of a multicenter, comparative epidemiological cohort study in Germany. In Vivo. 20:277-83.
98. Ho WS, Ying SY, Chan PC, Chan HH. (2006) Use of onion extract, heparin, allantoin gel in prevention of scarring in Chinese patients having laser removal of tattoos: a prospective randomized controlled trial. Dermatol. Surg. 32:891-6.
99. Asilian A, Darougheh A, Shariati F. (2006) New combination of triamcinolone, 5-fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatol. Surg. 32:907-15.
100. Zurada JM, Kriegel D, Davis IC. (2006) Topical treatments for hypertrophic scars. J. Am. Acad. Dermatol. 55:1024-31.
101. Berman B, Kaufman J. (2002) Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J. Am. Acad. Dermatol. 47:S209-11.
102. Berman B, et al. (2009) Treatment of keloid scars post-shave excision with imiquimod 5% cream: A prospective, double-blind, placebo-controlled pilot study. J. Drugs Dermatol. 8:455-8.
103. Prado A, Andrades P, Benitez S, Umana M. (2005) Scar management after breast surgery: preliminary results of a prospective, randomized, and double-blind clinical study with aldara cream 5% (imiquimod). Plast. Reconstr. Surg. 115:966-72.
104. Ferguson MW, et al. (2009) Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies. Lancet. 373:1264-74.
105. Bush J, et al. (2010) Therapies with emerging evidence of efficacy: avotermin for the improvement of scarring. Dermatol Res Pract 2010:690613.
106. Jalali M, Bayat A. (2007) Current use of steroids in management of abnormal raised skin scars. Surgeon. 5:175-80.
107. Cruz NI, Korchin L. (1994) Inhibition of human keloid fibroblast growth by isotretinoin and triamcinolone acetonide in vitro. Ann. Plast. Surg. 33:401-5.
108. Boyadjiev C, Popchristova E, Mazgalova J. (1995) Histomorphologic changes in keloids treated with Kenacort. J. Trauma. 38:299-302.
109. Robles DT, Berg D. (2007) Abnormal wound healing: keloids. Clin. Dermatol. 25:26-32.
110. Lawrence WT. (1991) In search of the optimal treatment of keloids: report of a series and a review of the literature. Ann. Plast. Surg. 27:164-78.
111. Boutli-Kasapidou F, Tsakiri A, Anagnostou E, Mourellou O. (2005) Hypertrophic and keloidal scars: an approach to polytherapy. Int. J. Dermatol. 44:324-7.
112. Jaros E, Priborsky J, Klein L. (1999) Treatment of keloids and hypertrophic scars with cryotherapy [in Czech]. Acta Medica (Hradec Kralove). Suppl. 42:61-3.
113. Yosipovitch G, et al. (2001) A comparison of the combined effect of cryotherapy and corticosteroid injections versus corticosteroids and cryotherapy alone on keloids: a controlled study. J. Dermatolog. Treat. 12:87-90.
114. Sharpe D. (1997) Of apples and oranges, file drawers and garbage: why validity issues in meta-analysis will not go away. Clin. Psychol. Rev. 17:881-901.
115. Rusciani L, Rossi G, Bono R. (1993) Use of cryotherapy in the treatment of keloids. J. Dermatol. Surg. Oncol. 19:529-34.
116. Zouboulis CC, Blume U, Buttner P, Orfanos CE. (1993) Outcomes of cryosurgery in keloids and hypertrophic scars: A prospective consecutive trial of case series. Arch. Dermatol. 129:1146-51.
117. Har-Shai Y, Amar M, Sabo E. (2003) Intralesional cryotherapy for enhancing the involution of hypertrophic scars and keloids. Plast. Reconstr. Surg. 111:1841-52.
118. Poochareon VN, Berman B. (2003) New therapies for the management of keloids. J. Craniofac. Surg. 14:654-7.
119. Zuber TJ, DeWitt DE. (1994) Earlobe keloids. Am. Fam. Physician. 49:1835-41.
120. Guix B, et al. (2001) Treatment of keloids by high-dose-rate brachytherapy: a seven-year study. Int. J. Radiat. Oncol. Biol. Phys. 50:167-72.
121. Ogawa R, Mitsuhashi K, Hyakusoku H, Miyashita T. (2003) Postoperative electron-beam irradiation therapy for keloids and hypertrophic scars: retrospective study of 147 cases followed for more than 18 months. Plast. Reconstr. Surg. 111:547-55.
122. Apfelberg DB, et al. (1984) Preliminary results of argon and carbon dioxide laser treatment of keloid scars. Lasers Surg. Med. 4:283-90.
123. Alster TS, Handrick C. (2000) Laser treatment of hypertrophic scars, keloids, and striae. Semin. Cutan. Med. Surg. 19:287-92.
124. Tanzi EL, Alster TS. (2004) Laser treatment of scars. Skin Therapy Lett. 9:4-7.
125. Alster T. (2003) Laser scar revision: comparison study of 585-nm pulsed dye laser with and without intralesional corticosteroids. Dermatol. Surg. 29:25-9.
126. Alster TS, Williams CM. (1995) Treatment of keloid sternotomy scars with 585 nm flashlamppumped pulsed-dye laser. Lancet. 345:1198-200.
127. Dierickx C, Goldman MP, Fitzpatrick RE. (1995) Laser treatment of erythematous/hypertrophic and pigmented scars in 26 patients. Plast. Reconstr. Surg. 95:84-92.
128. Chan HH, et al. (2004) The use of pulsed dye laser for the prevention and treatment of hypertrophic scars in Chinese persons. Dermatol. Surg. 30:987-94.
129. Fiskerstrand EJ, Svaasand LO, Volden G. (1998) Pigmentary changes after pulsed dye laser treatment in 125 northern European patients with port wine stains. Br. J. Dermatol. 138:477-9.
130. Hermanns JF, Petit L, Hermanns-Le T, Pierard GE. (2001) Analytic quantification of phototyperelated regional skin complexion. Skin. Res. Technol. 7:168-71.
131. Jimenez SA, Freundlich B, Rosenbloom J. (1984) Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J. Clin. Invest. 74:1112-6.
132. Berman B, Duncan MR. (1989) Short-term keloid treatment in vivo with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro. J. Am. Acad. Dermatol. 21:694-702.
133. Tredget EE, et al. (1998) Transforming growth factor- beta in thermally injured patients with hypertrophic scars: effects of interferon alpha-2b. Plast. Reconstr. Surg. 102:1317-28; discussion 1329-30.
134. Tredget EE, et al. (1998) Transforming growth factor-beta in thermally injured patients with hypertrophic scars: effects of interferon alpha- 2b. Plast. Reconstr. Surg. 102:1317-30.
135. Espana A, Solano T, Quintanilla E. (2001) Bleomycin in the treatment of keloids and hypertrophic scars by multiple needle punctures. Dermatol. Surg. 27:23-7.
136. Bodokh I, Brun P. (1996) Treatment of keloid with intralesional bleomycin [in French]. Ann. Dermatol. Venereol. 123:791-4.
137. Naeini FF, Najafian J, Ahmadpour K. (2006) Bleomycin tattooing as a promising therapeutic modality in large keloids and hypertrophic scars. Dermatol. Surg. 32:1023-30.
138. Saray Y, Gulec AT. (2005) Treatment of keloids and hypertrophic scars with dermojet injections of bleomycin: a preliminary study. Int. J. Dermatol. 44:777-84.
139. Apikian M, Goodman G. (2004) Intralesional 5- fluorouracil in the treatment of keloid scars. Australas. J. Dermatol. 45:140-3.
140. Fitzpatrick RE. (1999) Treatment of inflamed hypertrophic scars using intralesional 5-FU. Dermatol. Surg. 25:224-32.
141. Nanda S, Reddy BS. (2004) Intralesional 5-fluorouracil as a treatment modality of keloids. Dermatol. Surg. 30:54-7.